Yinzhe Xu

机构：State Grid Corporation of China (China), Anhui Medical University, Sydney College of Divinity, Beijing Institute of Genomics, Chinese PLA General Hospital, Soochow University, Nanjing Drum Tower Hospital, State Key Laboratory of Plant Genomics, Sino-Danish Centre for Education and Research, Ningxia Water Conservancy, Second Affiliated Hospital of Anhui Medical University, Shanghai Center For Bioinformation Technology · ORCID：0000-0002-8027-4559

发表论文 44 篇 · 总被引 1313 次 · h-index 16

代表论文

• Consensus Guidelines for the Use of Fluorescence Imaging in Hepatobiliary Surgery (2020 · Annals of Surgery · 被引 252)
• KAT8-catalyzed lactylation promotes eEF1A2-mediated protein synthesis and colorectal carcinogenesis (2024 · Proceedings of the National Academy of Sciences · 被引 247)
• Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients (2021 · Frontiers in Oncology · 被引 72)
• GOLM1 restricts colitis and colon tumorigenesis by ensuring Notch signaling equilibrium in intestinal homeostasis (2021 · Signal Transduction and Targeted Therapy · 被引 48)
• Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition) (2024 · BioScience Trends · 被引 20)
• NQO1/p65/CXCL12 Axis‐Recruited Tregs Mediate Resistance to Anti‐PD‐1 Plus Lenvatinib Therapy in PIVKA‐II‐Positive Hepatocellular Carcinoma (2025 · Advanced Science · 被引 8)